AUS
NZ
UK
CA
USA
IND
Highlights:
-
Haleon PLC has been upgraded by UBS, with an increased price target of 445p, reflecting confidence in the company’s long-term revenue prospects.
-
Despite a 3% reduction in adjusted earnings due to foreign exchange fluctuations, UBS remains optimistic about Haleon’s potential for 4-6% organic sales growth.
-
The Swiss bank has revised its estimate for Haleon’s long-term sales growth, increasing it to 2.5%, up from the previous 2%.
Haleon PLC {NYSE:HLN} , a consumer healthcare company, has received a favorable price target upgrade from UBS as anticipation builds ahead of its third-quarter update scheduled for October 31. This upgrade comes as UBS expresses growing confidence in Haleon’s long-term revenue opportunities.
While foreign exchange movements have led UBS to trim its estimates for Haleon’s adjusted earnings by 3%, the outlook remains positive overall. The Swiss bank highlighted that the GSK spin-out has demonstrated a strong capacity to achieve organic sales growth in the range of 4-6%. This robust performance is attributed to Haleon's diverse portfolio of well-known consumer healthcare brands, which are expected to continue performing well in various market conditions.
In addition to the earnings outlook, UBS has raised its assessment of Haleon’s terminal or 'forever' growth rate to 2.5%, an increase from the prior estimate of 2%. This adjustment reflects UBS's belief in the company’s ability to sustain growth over the long term, supported by its strategic initiatives and market positioning.
As a result of these developments, UBS has revised its price target for Haleon to 445p, up from 410p previously. This new price target signals a strong belief in Haleon’s growth potential and underscores the company’s role as a key player in the consumer healthcare sector. Shares of Haleon are currently trading at 379p, indicating room for potential appreciation in line with UBS’s upgraded outlook.
